Impact of SGLT2 inhibitors on cardiovascular outcomes and metabolic events in Chinese han patients with chronic heart failure
SGLT2i therapy not only enhances LVEF but also significantly reduces ambulatory blood pressure, uric acid, fasting blood glucose, pulmonary artery pressure, and NT-proBNP levels in CHF patients. Additionally, SGLT2i improves prognosis by lowering the risk of both primary and secondary endpoints. Compared to monotherapy, a four-drug regimen for CHF substantially reduces the risk of MACE, supporting the effectiveness of comprehensive treatment strategies.
Authors
- Fang Peng (ORCID: https://orcid.org/0000-0001-8877-3283)
- Jiawei Duan (ORCID: https://orcid.org/0000-0001-8979-1651)
- Jing Wan (ORCID: https://orcid.org/0000-0001-9183-477X)
- Rewaan Baheti
- Fei Li (ORCID: https://orcid.org/0000-0002-1732-6221)
- Wei Xiong (ORCID: https://orcid.org/0000-0001-5626-1427)
- Mengying Jin
Institutions
- Wuhan University (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Huangshi Central Hospital (CN)
Publication Details
- Journal
- Diabetology & Metabolic Syndrome
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s13098-024-01553-z
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.07
Funders
- Wuhan University
- Zhongnan Hospital of Wuhan University